Kane Biotech (KNE) Q2 2024 earnings summary

Executive summary

• Q2 2024 featured a $10.4M gain from the sale of a 67% interest in STEM Animal Health, resulting in net income of $9.2M and a strategic refocus on biofilm-mitigated topical infections, especially chronic non-healing wounds.

• All interest-bearing debt was repaid, leaving a debt-free and significantly strengthened balance sheet.

• Significant operational progress included manufacturing scale-up, regulatory advancements, and new distribution and license agreements.

Financial highlights

• Total revenue for Q2 2024 was $810,352, up 23% year-over-year from $657,000, with gross profit rising 41% to $464,453.

• Net income reached $9.2M, reversing a net loss of $968,000 in Q2 2023, primarily due to the STEM sale gain.

• Operating expenses increased 76% to $1.52M, mainly due to one-time, mostly non-cash items and manufacturing scale-up costs.

• License and royalty income rose 74% year-over-year to $299,992, mainly from Dechra agreement revenue recognition.

• Product and services revenue increased 5% year-over-year to $510,360, driven by contract manufacturing revenue.

Outlook and guidance

• Regulatory approval for Revive Antimicrobial Wound Gel in Canada is expected this quarter, with U.S. FDA clearance already obtained and expanded.

• Anticipated sales in Colombia, Panama, and Costa Rica early next year following regulatory submissions.

• Additional distribution agreements in the Middle East and further deals expected before year-end.

• Proof-of-concept trial for DispersinB in acne targeted to start this year; wound care trial initiation planned for H1 next year.

• Expects minimum annual royalties from new licensing agreements starting in 2025.